Y Intercept Hong Kong Ltd Invests $89,000 in Context Therapeutics Inc. (NASDAQ:CNTX)

Y Intercept Hong Kong Ltd bought a new stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 45,635 shares of the company’s stock, valued at approximately $89,000.

Several other institutional investors and hedge funds also recently bought and sold shares of CNTX. Great Point Partners LLC bought a new position in shares of Context Therapeutics in the second quarter worth about $14,876,000. Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $10,348,000. Driehaus Capital Management LLC bought a new stake in Context Therapeutics during the 2nd quarter worth approximately $4,527,000. Nantahala Capital Management LLC purchased a new position in Context Therapeutics during the second quarter valued at approximately $3,881,000. Finally, Ally Bridge Group NY LLC boosted its position in shares of Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $1.09 on Friday. The company has a market cap of $81.75 million, a P/E ratio of -1.20 and a beta of 2.00. Context Therapeutics Inc. has a 52-week low of $0.89 and a 52-week high of $2.75. The firm’s fifty day moving average is $1.80 and its two-hundred day moving average is $2.02.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, analysts forecast that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CNTX. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. D. Boral Capital assumed coverage on Context Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $9.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $6.80.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.